Literature DB >> 10626922

Anorexia nervosa in a Spanish adolescent sample: an 8-year longitudinal study.

C Pla1, J Toro.   

Abstract

OBJECTIVE: The aim of this study was to determine the intermediate-term outcome of a sample of Spanish children and adolescents with anorexia nervosa (AN).
METHOD: A total of 48 female patients were evaluated at a mean follow-up time of 8 years by means of the Psychiatric Status Rating Scale, the Morgan and Russell Outcome Scale, a structured DSM-III interview and several self-report questionnaires. Their scores were compared with a sex- and age-matched control group.
RESULTS: Three patients (6%) still had AN, two (4%) had partial syndromes of anorexia, 11 patients (23%) had recovered but still showed concern about food/body weight and 32 patients (67%) had recovered completely. The crude mortality rate was 2%.
CONCLUSION: The majority of this sample of children and adolescents with anorexia nervosa sample recovered. Perfectionism and interpersonal distrust were significantly more common in the anorexic patients than in the controls. Depression and phobias, including social phobia, were the most common comorbid psychiatric diagnoses at follow-up.

Entities:  

Mesh:

Year:  1999        PMID: 10626922     DOI: 10.1111/j.1600-0447.1999.tb10894.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  2 in total

1.  The adolescent onset anorexia nervosa study (ANABEL): Design and baseline results.

Authors:  Montserrat Graell; Patricia de Andrés; Ana Rosa Sepúlveda; Alba Moreno; Ángel Villaseñor; Mar Faya; Carmen Martínez-Cantarero; Sonia Gómez-Martínez; Ascensión Marcos; Gonzalo Morandé; Esther Nova
Journal:  Int J Methods Psychiatr Res       Date:  2018-08-21       Impact factor: 4.035

2.  Hospital admission and mortality rates in anorexia nervosa: experience from an integrated medical-psychiatric outpatient treatment.

Authors:  E De Filippo; A Signorini; R Bracale; F Pasanisi; F Contaldo
Journal:  Eat Weight Disord       Date:  2000-12       Impact factor: 4.652

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.